Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice (REPIN)

National Society for Neurosonology and Cerebral Circulation

Status: Enrolling

Conditions: Acute Stroke

Study type: Observational

Funder types: Other

Identifiers

NCT05697575

REPIN-Forte

Details and patient eligibility

About

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

Enrollment: 336 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-85 ;
• Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;
• Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.

Exclusion criteria

• Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;
• The presence of a contraindication to thrombolytic therapy of ischemic stroke;
• Pregnancy or lactation.